DK1377298T3 - Exemestan til behandling af hormon-afhængige lidelser - Google Patents

Exemestan til behandling af hormon-afhængige lidelser

Info

Publication number
DK1377298T3
DK1377298T3 DK02727314T DK02727314T DK1377298T3 DK 1377298 T3 DK1377298 T3 DK 1377298T3 DK 02727314 T DK02727314 T DK 02727314T DK 02727314 T DK02727314 T DK 02727314T DK 1377298 T3 DK1377298 T3 DK 1377298T3
Authority
DK
Denmark
Prior art keywords
exemestane
hormone
treatment
dependent disorders
disorders
Prior art date
Application number
DK02727314T
Other languages
Danish (da)
English (en)
Inventor
Salle Enrico Di
Gans Hendrik Dekoning
Dinesh Purandare
Gabriella Piscitelli
Giorgio Massimini
Original Assignee
Pfizer Italia Srl
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia Srl, Pharmacia & Upjohn Co Llc filed Critical Pfizer Italia Srl
Application granted granted Critical
Publication of DK1377298T3 publication Critical patent/DK1377298T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02727314T 2001-01-26 2002-01-18 Exemestan til behandling af hormon-afhængige lidelser DK1377298T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77091101A 2001-01-26 2001-01-26

Publications (1)

Publication Number Publication Date
DK1377298T3 true DK1377298T3 (da) 2007-01-02

Family

ID=25090093

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02727314T DK1377298T3 (da) 2001-01-26 2002-01-18 Exemestan til behandling af hormon-afhængige lidelser

Country Status (12)

Country Link
EP (1) EP1377298B1 (fr)
JP (1) JP2004519490A (fr)
AR (1) AR032268A1 (fr)
AT (1) ATE337787T1 (fr)
CA (1) CA2434611A1 (fr)
DE (1) DE60214355T2 (fr)
DK (1) DK1377298T3 (fr)
ES (1) ES2269682T3 (fr)
MX (1) MXPA03006607A (fr)
PE (1) PE20020843A1 (fr)
PT (1) PT1377298E (fr)
WO (1) WO2002072106A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
WO2003017974A1 (fr) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Methode de traitement des troubles gynecologiques benins et trousse pharmaceutique destinee a etre utilisee dans ladite methode
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
US20060173062A1 (en) * 2003-06-20 2006-08-03 Boice Judith A Use of selective cyclooxygenase-2 inhibitors for the treatment of endometriosis
WO2007062093A2 (fr) * 2005-11-22 2007-05-31 Incyte Corporation Polytherapie pour le traitement du cancer
KR20160033796A (ko) 2006-03-28 2016-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
US20100087407A1 (en) * 2006-08-04 2010-04-08 James Symons use of aromatase inhibitors
CN101717393A (zh) * 2009-12-01 2010-06-02 陈依军 环己基2,5-二取代苯基醚的衍生物及其应用
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
KR101698238B1 (ko) 2010-06-10 2017-01-19 세라곤 파마슈티컬스, 인크. 에스트로겐 수용체 조정제 및 이의 용도
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
HRP20211836T1 (hr) 2013-09-24 2022-03-04 Fujifilm Corporation Novi spoj koji sadrži dušik ili njegova sol, ili njegov metalni kompleks
CA3008023A1 (fr) 2015-12-30 2017-07-06 Saint Louis University Derives d'acide aminobenzoique meta-azacyclique a titre d'antagonistes de pan-integrine
CN113712974A (zh) * 2021-08-20 2021-11-30 南京大学 阿司匹林在制备治疗子宫内膜增生药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
GB8617107D0 (en) * 1986-07-14 1986-08-20 Erba Farmitalia 6-/7-methylenandrosta-1 4-diene-3 17-dione derivatives
JPH07506120A (ja) * 1993-02-18 1995-07-06 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー フッ素化４−アミノアンドロスタジエノン誘導体及びその製造方法
GB9313420D0 (en) * 1993-06-29 1993-08-11 Erba Carlo Spa Fluorinated 6-methylenandrosta-1,4-dien-3-one-derivatives and process for their preparations
WO2000038715A2 (fr) * 1998-12-23 2000-07-06 G.D. Searle & Co. Procede d'utilisation d'un antagoniste de l'integrine et radiotherapie en tant que polytherapie dans le traitement des neoplasies
EA005931B1 (ru) * 2000-05-15 2005-08-25 Фармация Италия С.П.А. Ингибиторы ароматазы и моноклональные антитела против her2 как противоопухолевые агенты
AU8986501A (en) * 2000-09-08 2002-03-22 Pharmacia & Upjohn Spa Exemestane as chemopreventing agent

Also Published As

Publication number Publication date
AR032268A1 (es) 2003-10-29
DE60214355T2 (de) 2007-08-30
CA2434611A1 (fr) 2002-09-19
EP1377298B1 (fr) 2006-08-30
WO2002072106A2 (fr) 2002-09-19
JP2004519490A (ja) 2004-07-02
PE20020843A1 (es) 2002-09-25
ATE337787T1 (de) 2006-09-15
DE60214355D1 (de) 2006-10-12
MXPA03006607A (es) 2003-09-22
ES2269682T3 (es) 2007-04-01
WO2002072106A3 (fr) 2003-10-30
EP1377298A2 (fr) 2004-01-07
PT1377298E (pt) 2006-12-29

Similar Documents

Publication Publication Date Title
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
DK0967214T3 (da) Intranasale formuleringer til behandling af seksuelle forstyrrelser
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK1451143T3 (da) Fremgangsmåder til fremstilling af O-desmethylvenlafaxin
DK1427437T3 (da) Oxyntomodulin til forebyggelse eller behandling af overvægt
DK1223927T3 (da) Anvendelse af retigabin til behandling af neuropatiske smerter
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1277722T3 (da) Fremgangsmåde til fremstilling af methanol
DK1711530T3 (da) Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DK1143977T3 (da) 2-oxy-benzoxazinonderivater til behandling af obesitas
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DK1380121T3 (da) Fremgangsmåde til fremstilling af oxazolidinoner
DK1377298T3 (da) Exemestan til behandling af hormon-afhængige lidelser
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
DK1407037T3 (da) Fremgangsmåde til fremstilling af tagatose
DK1324970T3 (da) Retinoider til behandling af emfysem
DK1206436T3 (da) Retinoider til behandling af emfysem
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose